Anticoagulation Therapy for Atrial Fibrillation and Flutter

Introduction to Anticoagulation Therapy

• The American College of Chest Physicians recommends that patients with atrial flutter who have undergone successful cardioversion should continue anticoagulation therapy for at least 4 weeks after cardioversion, regardless of baseline stroke risk, with subsequent long-term anticoagulation decisions based on the patient's CHA₂DS₂-VASc score 1, 2

Anticoagulation Duration and Method

• All patients with atrial flutter who undergo successful cardioversion require therapeutic anticoagulation for a minimum of 4 weeks after restoration of sinus rhythm, regardless of the method of cardioversion, baseline stroke risk, or pre-cardioversion anticoagulation administration 1, 2, 3
• Therapeutic anticoagulation is required for at least 3 weeks before cardioversion and should be continued for a minimum of 4 weeks after successful cardioversion, regardless of baseline stroke risk, with options including Vitamin K antagonist (VKA) and Direct oral anticoagulant (DOAC) such as apixaban, dabigatran, rivaroxaban, or edoxaban, as recommended by the American College of Chest Physicians 1, 4

Anticoagulation Agents

• The target INR for vitamin K antagonists, such as warfarin, is 2.0-3.0, with a recommended time in therapeutic range (TTR) of ≥70% 1
• The SAMe-TT₂R₂ score can be used to identify patients likely to do well on vitamin K antagonists 1
• Direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban, apixaban, or edoxaban, are reasonable alternatives to vitamin K antagonists, particularly for patients with poor TTR on warfarin 1, 2
• Adherence and persistence with DOAC therapy should be emphasized 1

Stroke Risk Assessment

• The CHA₂DS₂-VASc score is used to assess stroke risk, with the following points assigned:

• Men with CHA₂DS₂-VASc ≥ 2 or women with score ≥ 3 should continue long-term anticoagulation indefinitely, while men with CHA₂DS₂-VASc = 1 or women with score = 2 should consider long-term anticoagulation, and men with CHA₂DS₂-VASc = 0 or women with score = 1 generally do not require anticoagulation after initial 4 weeks, as recommended by the European Society of Cardiology and the European Heart Journal 5, 6

Rate and Rhythm Control

• The American College of Cardiology recommends a rate control strategy as preferred for most patients, especially older adults with minimal symptoms, with a target heart rate of 60-100 bpm at rest and 90-115 bpm during moderate exercise, and beta-blockers as first-line medication for rate control, with non-dihydropyridine calcium channel blockers (diltiazem/verapamil) as alternative for patients with LVEF >40%, as recommended by the American College of Cardiology and the European Heart Journal 7, 6
• Consider digoxin for patients with heart failure, as recommended by the American College of Cardiology 7
• Consider rhythm control strategy for younger patients (<65 years), highly symptomatic patients despite adequate rate control, patients with difficulty achieving rate control, first episode of AF, or AF precipitated by corrected acute illness, as recommended by the European Heart Journal 6

Follow-up and Monitoring

• Schedule follow-up within 2-4 weeks to assess maintenance of sinus rhythm, medication adherence and side effects, and need for dose adjustments
• Perform ECG at 1, 3, 6, and 12 months after cardioversion to assess for AF recurrence, medication side effects, bleeding complications with anticoagulation, and control of comorbidities, as recommended by the American College of Chest Physicians 1

Prevention of Recurrence and Complications

• Aggressively treat modifiable risk factors, including hypertension, heart failure, diabetes, obesity, sleep apnea, and alcohol consumption, to reduce AF recurrence rates, as recommended by the European Heart Journal 6
• Discontinuing anticoagulation too early, even if sinus rhythm is maintained, can increase stroke risk, as warned by the American College of Chest Physicians 1
• Focusing solely on rhythm control may not provide mortality benefit and may be associated with more hospitalizations, as shown by the AFFIRM trial, with a Class I recommendation and Level B-R evidence 8
• Both conventional and TEE-guided approaches have comparable safety profiles with low stroke risk (0.5-0.8%), with a Class I recommendation and Level B-R evidence, and the European Heart Journal notes that most thromboembolic events occur within 10 days after cardioversion, highlighting the importance of adequate anticoagulation, with a strong recommendation (Class I) and moderate quality evidence 9, 10